Background: This descriptive study aimed to determine the serum level of alpha-1 antitrypsin (AAT) in patients with severe asthma.
INTRODUCTION
Asthma is a syndrome characterized by airflow obstruction that noticeably varies with or without treatment. Narrowing of the airways is usually reversible, but some patients with chronic asthma may suffer irreversible airflow obstruction. The increasing global prevalence of asthma and high health care costs have led to extensive researches about its mechanism and treatment.
Bronchial asthma has a wide clinical spectrum ranging from a mild intermittent disease to one that is severe, persistent and difficult to treat, which can also be fatal in some cases (1) .
The National Institute of Health Guidelines for the Diagnosis and Management of Asthma have characterized severe persistent asthma in untreated patients by several criteria: continual symptoms (also occurring frequently at night) that cause limitations in physical activities; frequent exacerbations; persistent airflow obstruction with forced expired volume in 1 sec (FEV1) less than 60% of the predicted value and peak expiratory flow (PEF) diurnal variability greater than 30% (2).
The AAT is a principal inhibitor of serum protease that is mainly secreted by hepatocytes and to a minor extent, by monocytes, pancreatic islets, lung alveolar cells and colonic enterocytes. Significant reductions in serum and tissue AAT levels in human beings are associated with chronic obstructive pulmonary disease (COPD) especially pulmonary emphysema and liver disease which can lead to cirrhosis, necrotizing panniculitis and vasculitis (3, 4) .
The AAT deficiency as an autosomal and co-dominant genetic disorder is characterized by decreased concentration and activity of the AAT in blood and tissues (5) . Although some degrees of the AAT deficiency are somewhat more common worldwide, its severe deficiency (the AAT serum levels less than 11µmol or 50 mg/dl) is a rare occurrence (6, 7) .
TANAFFOS
In a cohort study of 1052 subjects with AAT deficiency, researchers reported that signs and symptoms of asthma were frequent in AAT deficiency and may start at the age of most rapid FEV1 loss (8) . In AAT deficiency, augmentation therapy cannot effectively prevent the loss of lung function in asthmatic patients as compared to nonasthmatic patients (9) .
However, some reports about COPD show that AAT therapy had good results in some patients with COPD and AAT deficiency. According to these reports augmentation therapy improves lung function in subjects with AAT deficiency when adjusted for age, gender, smoking status and baseline FEV1 % of the predicted value. The beneficial effects were noted in ex-smoker subjects with FEV1 less than 50% of the predicted value (10, 11) . On the base of recent studies about asthma and its relation with AAT deficiency, the results could not distinguish the impact of asthma on the course of irreversible airflow obstruction in severe AAT deficiencies (12, 13) .
In this study, we determined the serum level of AAT in patients with severe asthma in order to show whether AAT deficiency is a risk factor of persistent airflow limitation in patients with asthma or not. If we find reasonable relation between the AAT level and asthma, we can improve treatment of severe asthma with AAT replacement therapy (14, 15) . 
MATERIALS AND METHODS

RESULTS
In this study, 43 patients (69.8% males, 30.2% females)
were evaluated with severe asthma and a mean age of 41±13.8 years. The measured AAT level was normalized and is shown in Figure 1 . The clinical characteristics, AAT levels, spirometry findings and demographic findings are listed in Table 1 . After determination of the AAT level in these patients, we found that it was within the normal range (90 -200 mg/dl) in 38 patients (88.4%) and was less than normal in 2 patients (4.7%). In our study, there was no significant correlation between sex and AAT level (P=0.44), FEV 1 However, one investigation on asthmatic children observed that patients with severe AAT deficiency were susceptible to early decrease of lung function (18) .
Additionally, in a cohort study by Eden et al, it was shown that asthmatic features were prevalent in severe AAT deficiencies and symptoms appeared earlier (7). This finding is probably due to elevated levels of total serum immunoglobulin E (IgE) in these patients which can be responsible for the accelerated decrease of FEV 1 .
Considering the high number of asthmatic patients with persistent air-flow limitation, we expected to have a much higher prevalence of AAT deficiency (19) . But our results indicated that AAT deficiency cannot be a risk factor for development of persistent airflow limitation in asthmatic patients. Therefore, the efficacy of AAT replacement therapy would possibly be low for prevention of the lung function decline. Due to the limitations of this study (small sample size), our findings need to be confirmed by prospective longitudinal studies on a larger group of asthmatic patients.
In conclusion, we found that AAT deficiency cannot be a risk factor for persistent air-flow restriction in patients with asthma and the prevalence of AAT deficiency in patients with severe asthma was not considerable.
